R 412
Alternative Names: R-412Latest Information Update: 11 Sep 2023
At a glance
- Originator Radikal Therapeutics
- Class Chemokines; Small molecules
- Mechanism of Action Regulatory T-lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal disorders; Multiple sclerosis; Pulmonary fibrosis; Sepsis; Type 1 diabetes mellitus
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Gastrointestinal disorders in USA (SC)
- 11 Sep 2023 Discontinued - Preclinical for Multiple sclerosis in USA (SC)
- 11 Sep 2023 Discontinued - Preclinical for Pulmonary fibrosis in USA (SC)